Scailyte CHU Rennes announce Covid-19 partnership. Scailyte AG, a Swiss startup in the emerging and rapidly growing field of single-cell technologies, raised CHF 3.1 million in a pre-Series A round led by Swisscom Ventures.
Scailyte AG was founded in Luzern, Switzerland in July 2017. Scailyte is an ETH Zurich spin-off and is
supported by Innosuisse (Swiss Innovation Agency). The company has gained recognition by winning
several national and international start-up competitions, and is the beneficiary of significant research
grants. Scailyte has a multi-disciplinary team with expertise in Cell biology, Genetics, Artificial
Intelligence, Software development, Finance, Marketing and Sales.
The ScaiVision™ biomarker discovery platform delivers best-in-class performance for supervised
pattern recognition analysis of single-cell data. The performance and clinically-relevant application of the core deep learning algorithm of ScaiVision have been validated in several scientific papers and
have resulted in patent-pending diagnostic applications. For more information visit www.scailyte.com
Scailyte™ and ScaiVision™ are registered trademarks proprietary to Scailyte AG.
Recent News
Scailyte and Sanofi Collaboration Solves Critical Manufacturing Challenge for NK Cell Therapy, New Paper Reveals
Scailyte's AI-driven ScaiVision™ platform successfully identified a predictive biomarker for manuf...
Recent News
Scailyte Awarded CHF 800K Innosuisse Grant to Drive Precision Medicine in Inflammatory Bowel Disease (IBD)
Project AIomics will unite Scailyte's AI discovery platform with the Swiss IBD Cohort and Universit...
Recent News
Scailyte and Visterra Partner to Advance Autoimmune Disease Research
Scailyte AG, an AI-driven biomarker discovery company, and Visterra, Inc., a clinical-stage biopharm...
Recent News
Scailyte Strengthens Its Leadership
Scailyte appoints Tim Foley as Chief Business Officer, Jean-Pierre Rosat as Executive Chair, and Dar...
Recent News
Scailyte Announces Virginia Savova, PhD as a Strategic and Scientific Advisor
Scailyte Announces Virginia Savova, PhD as a Strategic and Scientific Advisor. Dr. Savova brings str...
Recent News
Scailyte Extends Series A to USD 8 Million
We are thrilled to announce the extension of our Series A funding, bringing the total raised amount ...
Recent News
Unravelling the AI Executive Order: A Discussion with Our CEO and Head of Regulatory Affairs
We invite you to watch this enlightening discussion to gain valuable insights into the evolving AI l...
Recent News
Scailyte and MaxiVAX Solve Clinical Challenges with Data-Driven Collaboration
Scailyte and MaxiVAX, two cutting-edge precision medicine organizations, proudly announce their coll...
Recent News
Scailyte and Sanofi Collaboration Solves Critical Manufacturing Challenge for NK Cell Therapy, New Paper Reveals
Scailyte's AI-driven ScaiVision™ platform successfully identified a predictive biomarker for manuf...
Scailyte Awarded CHF 800K Innosuisse Grant to Drive Precision Medicine in Inflammatory Bowel Disease (IBD)
Project AIomics will unite Scailyte's AI discovery platform with the Swiss IBD Cohort and Universit...
Recent News
Scailyte and Visterra Partner to Advance Autoimmune Disease Research
Scailyte AG, an AI-driven biomarker discovery company, and Visterra, Inc., a clinical-stage biopharm...
Scailyte Strengthens Its Leadership
Scailyte appoints Tim Foley as Chief Business Officer, Jean-Pierre Rosat as Executive Chair, and Dar...
Recent News
Scailyte Announces Virginia Savova, PhD as a Strategic and Scientific Advisor
Scailyte Announces Virginia Savova, PhD as a Strategic and Scientific Advisor. Dr. Savova brings str...
Scailyte Extends Series A to USD 8 Million
We are thrilled to announce the extension of our Series A funding, bringing the total raised amount ...
Recent News
Unravelling the AI Executive Order: A Discussion with Our CEO and Head of Regulatory Affairs
We invite you to watch this enlightening discussion to gain valuable insights into the evolving AI l...
Scailyte and MaxiVAX Solve Clinical Challenges with Data-Driven Collaboration
Scailyte and MaxiVAX, two cutting-edge precision medicine organizations, proudly announce their coll...